Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition

benzinga.com/news/health-care/25/11/48931416/mercks-winrevair-success-extends-beyond-pulmonary-hypertension-showing-promise-in-complex-heart-

Merck & Co. Inc. (NYSE:MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF).
• MRK is among…

This story appeared on benzinga.com, 2025-11-18 17:42:18.
The Entire Business World on a Single Page. Free to Use →